Anthia Govender | Medical Biochemistry | Best Researcher Award

Ms. Anthia Govender | Medical Biochemistry | Best Researcher Award

PhD student at University of Kwa-Zulu Natal, South Africa

Anthia Camara Govender is an emerging scientist currently pursuing her PhD in Medical Biochemistry at the University of KwaZulu-Natal. With a strong academic background and early research contributions in toxicology and epigenetics, she has quickly established herself as a promising researcher in the biomedical field. Anthia’s work primarily investigates the cellular and molecular effects of environmental toxins such as mycotoxins, with a specific focus on their impact on lung tissue and genetic regulation. Her dedication to uncovering new insights in medical biochemistry reflects a clear commitment to advancing translational science and therapeutic strategies.

profile

orcid

Education

Anthia’s academic journey began with her matriculation from Sathya Sai School, Chatsworth, in 2019. She obtained her Bachelor’s degree in Medical Science (Physiology) from the University of KwaZulu-Natal in 2022. Her strong academic performance continued as she graduated cum laude in both her Honours in Medical Science (Medical Biochemistry) in 2023 and her Master’s degree in Medical Science (Medical Biochemistry) in 2024. Currently, she is enrolled in a PhD program at the same university, focusing her doctoral research on the toxicological effects of fumonisins on pulmonary epigenetics and cellular dysfunction.

Experience

Although at the early stage of her professional career, Anthia has already undertaken significant research responsibilities through her postgraduate projects. Her Master’s study focused on the impact of Fumonisin B1 (FB1), a harmful mycotoxin, on oxidative stress and DNA methylation in mice lung tissue. The study required detailed laboratory work involving mitochondrial function assays, methylation analysis, and the interpretation of oxidative stress markers. Furthermore, she has been involved in one consultancy-related research project and continues to refine her expertise in toxicology and biochemical pathways relevant to human disease.

Research Interest

Anthia’s research interests are deeply rooted in medical biochemistry, with a focus on toxicology, mycotoxins, epigenetics, and oxidative stress. Her academic progression into PhD-level work demonstrates a growing interest in exploring how environmental toxins disrupt biological systems at a molecular level. She is particularly fascinated by the mechanisms of mitophagy, DNA hypermethylation, and how these contribute to disease pathogenesis. Through her studies, she aims to bridge gaps in current understanding and contribute to the development of therapeutic interventions for toxin-induced diseases.

Award

Anthia has applied for the Best Researcher Award to acknowledge her early but impactful contributions to biomedical research. Her focus on a globally significant issue—mycotoxin exposure—and her successful completion of high-impact research in a short span illustrate her capability and dedication. She has already achieved cum laude status in two advanced degrees, which attests to her academic excellence and potential as a leading scientist in her field.

Publication

Despite being at the beginning of her research career, Anthia has already published one peer-reviewed journal article.

  • Govender AC (2024). “Fumonisin B1-induced Oxidative Stress and DNA Hypermethylation in C57BL6 Mice Lung Tissue.” Journal of Toxicologic Pathology, 37(2): 145–155. [Cited by 2 articles].

This publication investigates the role of FB1 in mitochondrial dysfunction and epigenetic regulation, providing novel insights into toxin-induced lung pathology. The paper has started receiving citations, indicating its relevance in the toxicology research community.

Conclusion

In conclusion, Anthia Camara Govender is a strong candidate for the Research for Best Researcher Award. Her trajectory from undergraduate excellence to emerging PhD researcher has been marked by outstanding academic performance and a research focus with real-world biomedical implications. Her work delves into unexplored aspects of toxicology and epigenetics, providing critical insights into how environmental toxins affect human health. Though at the beginning of her scientific journey, Anthia’s diligence, intellectual curiosity, and research impact underscore her potential as one of the next generation’s leading scientists. Her nomination for this award is both timely and well-deserved.

Dilek Gungor | Biochemistry | Best Researcher Award

Mr. Dilek Gungor | Biochemistry | Best Researcher Award

Postdoctoral Researcher at Department of Basic Pharmaceutical Sciences, Faculty of Pharmacy, Hacettepe University, 06100 Ankara, Turkey

Dilek Güngör is a researcher in forensic biochemistry and nanomedicine with a strong academic background and multidisciplinary experience. Her work focuses on innovative drug delivery systems, particularly in combating antimicrobial resistance. Through research roles at both national institutions and internationally renowned universities, she has established a profile marked by scientific curiosity, methodical rigor, and impactful contributions to pharmaceutical and forensic sciences.

profile

orcid

Education

Dilek completed her Ph.D. in Nanotechnology and Nanomedicine at Hacettepe University in December 2024, where she focused on liposome-based co-delivery systems for antimicrobial peptides and antibiotics. Her doctoral studies included an international research stint at Rutgers University in the U.S., supported by TÜBİTAK 2214/A. She earned her M.Sc. in Biochemistry (Pharmacy) from Gazi University in February 2018 and her B.Sc. in Biochemistry with a specialization in Biotechnology from Ege University in June 2009. Her academic formation reflects a consistent commitment to molecular and pharmaceutical sciences, with thesis work investigating gene expressions in cancer and novel therapeutic delivery platforms.

Experience

Dilek has served as a Research Assistant at the Turkish National Police Academy across several departments since 2014, currently contributing to the Forensic Science Department. Between 2022 and 2023, she was a Visiting Scholar at Rutgers University’s Center for Dermal Research, deepening her expertise in transdermal drug delivery systems. Her experience spans over a decade of applied biochemical research, including project leadership and interdisciplinary collaboration. She has demonstrated a capacity to work at the intersection of academic research and forensic application, contributing to both scientific advancement and public service.

Research Interest

Her research interests include nanomedicine, forensic toxicology, and dermal drug delivery systems. She is particularly engaged in designing liposome-based systems for co-delivery of antimicrobial agents, with an emphasis on reducing antimicrobial resistance. Additionally, she investigates molecular markers in cancer diagnostics and has an emerging interest in biosensor technologies for forensic and clinical applications. Her research is characterized by translational intent, targeting real-world medical and forensic challenges through molecular innovation.

Awards

Dilek has been recognized with a TÜBİTAK 2214-A International Research Fellowship, allowing her to pursue advanced pharmaceutical research abroad. Earlier in her career, she contributed to a TÜBİTAK 2209-A project on biosensor development during her undergraduate studies. These fellowships underscore both her scientific promise and her capacity to lead cutting-edge research in nationally and internationally competitive contexts.

Publications

Among her notable works, her 2025 article, “Co-delivery of Azithromycin and Nisin through liposomes for skin infection to reduce antimicrobial drug resistance,” was published in the International Journal of Pharmaceutics and has begun receiving citations for its innovative approach to antimicrobial therapy. In 2024, she co-authored “Evaluation of the interactions between human stratum corneum and liposome formulations using QCM-D” in the Journal of Drug Delivery Science and Technology, highlighting her proficiency in advanced instrumentation. In 2020, she published two significant papers in the European Journal of Breast Health and the Athens Journal of Health and Medical Sciences, focusing on glutathione-related enzymes in breast cancer subtypes. Her earlier publication, “Sentetik uyuşturucular: Amfetamin örneği,” appeared in the Güvenlik Çalışmaları Dergisi in 2018 and reflects her forensic research contributions. Her most cited article is the 2025 IJPharm paper on liposomal drug delivery for antimicrobial resistance, which is increasingly referenced in pharmaceutical and clinical research circles.

Conclusion

Dr. Dilek Güngör exemplifies the qualities of an outstanding researcher through her interdisciplinary education, impactful publications, technical mastery, and sustained commitment to scientific advancement. Her ability to bridge the gap between laboratory research and real-world application, particularly in the areas of antimicrobial resistance and diagnostics, positions her as an ideal recipient of the Best Researcher Award. Her trajectory reflects both depth and breadth of expertise, making her a valuable asset to the scientific community at large